Preservica
30.1.2024 15:12:31 CET | ACCESS Newswire | Press release
GSK Selects Preservica Enterprise for its Corporate Archive, Ushering in a New Era of Digital Asset Resilience and Accessibility in Pharmaceuticals
BOSTON, MA and OXFORD, UK / ACCESSWIRE / January 30, 2024 / Preservica, a global leader in Active Digital Preservation™ archiving, is thrilled to announce GSK (GlaxoSmithKline), a multinational pharmaceutical and biotechnology company, has officially chosen Preservica as its Digital Preservation and archiving supplier for their Corporate Heritage Archives.
As a global leader in uniting science, technology and talent, GSK opted for Preservica's Enterprise edition with Active Digital Preservation™, ensuring not only the secure storage of historical records but also the continuous management, accessibility and protection of critical corporate governance and compliance documents in a way that goes beyond conventional archiving solutions.
The choice of Digital Preservation reflects a strategic decision to ensure the accessibility, integrity and longevity of these records. By leveraging Preservica, GSK not only fulfills its archival needs but also establishes a foundation to inform and protect the future of the business, offering valuable insights for strategic decision-making and ensuring a robust framework for regulatory compliance and brand continuity.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.GSK employee working in tuberculosis imaging laboratory at Tres Cantos site, Madrid
"After a comprehensive evaluation of preservation solutions, we confidently selected Preservica," said Jill Moretto, Senior Information Governance and Heritage Archive Manager. "Preservica automates our content migration workflows and also integrates seamlessly with our collections management system, Qi. Overall, it's simplifying our processes and eliminating duplicative work for the GSK Heritage team. This streamlined workflow is instrumental in documenting our contributions and legacy in health, science, industry, culture and the community, showcasing our impact on a global scale. Preservica completes GSK Heritage's core needs as a corporate archive. I'm so excited to use it to protect our legacy as we continue to get ahead of disease together."
Preservica Enterprise solution seamlessly integrates all essential elements for successful Digital Preservation, including public and secure access. The Enterprise edition not only meets but exceeds core requirements, offering a singular, integrated application that delivers comprehensive, scalable and fully compliant protection for critical long-term assets.
"This partnership stands as a testament to Preservica's commitment to advancing digital preservation standards across industries," said Preservica CEO, Mike Quinn. "Preservica is proud to contribute to the resilience and longevity of digital assets in an arena where historical data integrity directly influences advancements in healthcare and pharmaceutical breakthroughs."
The collaboration focuses on bolstering internal and external communications, as well as supporting marketing initiatives through the preservation of diverse file formats, including AV, TIFF, JPEG and standard office formats.
For more information on how Preservica is part of an international community of pharmaceutical institutions worldwide that are choosing Preservica as their trusted partner for Digital Preservation, visit preservica.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at gsk.com.
About Preservica
Preservica is transforming the way organizations around the world protect and future-proof critical long-term digital information. Available in the cloud (SaaS) or on-premise, our award-winning Active Digital Preservation™ archiving software has been designed from the ground up to tackle the unique challenges of ensuring digital information remains accessible and trustworthy over decades.
It's a proven solution that's trusted by thousands of businesses, archives, libraries, museums and government organizations around the world, including the UK National Archives, Texas State Library and Archives, MoMA, Yale and HSBC.
preservica.com
Twitter: @Preservica
LinkedIn: @Preservica
Media Contact:
Aleeza Goodman
York IE
aleeza@york.ie
SOURCE: Preservica
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Proxymity Unveils MiKaDiv Compliance Solution for Issuers Ahead of New German Tax Regime18.11.2026 08:30:00 CET | Press release
FRANKFURT AM MAIN, DE / ACCESS Newswire / November 18, 2026 / Proxymity, the digital investor communications platform, is set to launch its MiKaDiv Compliance Solution as Germany's new dividend reporting regime takes effect in January 2027, giving German issuers a single place to manage their new obligations to the Federal Central Tax Office (BZSt). From 1 January 2027, dividends paid by listed German companies will carry an additional reporting step: the company must pass details of its shareholders to the BZSt. SRD II, transposed into German law under Section 67d of the German Stock Corporation Act, (AktG) took effect in 2020 and gave issuers the right to identify their investors, including foreign investors held through nominee accounts. MiKaDiv now makes it a requirement. The first reports are expected early in the 2027 AGM season, as issuers seek approval for their dividends. Proxymity is the leading provider of shareholder identification to German issuers, handling more than 40%
QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release
CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release
PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning
OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
